European Journal of Dermatology
MENUParaneoplastic pemphigus associated with myasthenia gravis and Castleman’s tumour Volume 7, issue 5, July - August 1997
Figures
Department of Internal Medicine 2, Cochin Hospital, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
- Key words: Sweet’s syndrome, G-CSF, myeloma, adverse effect, interleukin-6.
- Page(s) : 371-3
- Published in: 2000
A 66-year-old man was treated with cyclophosphamide for multiple myeloma. G-CSF (300 mm/day for 14 days) was administred for blood stem cell collection. Twenty four hours after G-CSF was discontinued, he presented a cutaneous Sweet’s syndrome, which was confirmed by histology. There were no other symptoms and neutrophil count was 6.2 x 109/l. A few cases of Sweet’s syndrome have been discribed in association with G-CSF. This growth factor stimulates production of neutrophils and appears to be involved in the physiopathology of Sweet syndrome, probably in association with IL6.